leaders-staging.thebearpit.com
Leaders' Quest | Banking Futures
http://leaders-staging.thebearpit.com/banking-futures
Lindsay Levin’s BSR talk. Please do not fill-in this field. T 44 20 8948 5200. New York, NY 10001. T 1 646 630 7336. E darya.shaikh@leadersquest.org. Ground Floor, 37 Bridget House. Mumbai 400 050, India. T 91 22 2605 9745. E sasha.rodricks@leadersquest.org. T 44 20 8948 5200. New York, NY 10001. T 1 646 630 7336. E darya.shaikh@leadersquest.org. Ground Floor, 37 Bridget House. Mumbai 400 050, India. T 91 22 2605 9745. E daniel.lobo@leadersquest.org. Building a healthy banking sector. What is our goal?
pharmafutures.org
Context | Pharmafutures
http://pharmafutures.org/what-is-pharmafutures/context
Helping align corporate profitability with improved access to innovative and affordable healthcare. Scenario Planning A 20-Year Outlook. Uncovering Value Drivers A 5 to 10 Year Perspective. Identifying Opportunities Exploring Today’s Innovative Models for Value Creation. Shared Value – Rebuilding Pharma’s Contract with Society. Innovation in health systems. John Schaetzl, Independent.
pharmafutures.org
Shared Value | Pharmafutures
http://pharmafutures.org/pharmafutures-4
The R&D Challenge. From Challenge to Opportunity. Pharma and the Environment. The report concludes that the industry needs to reframe its social contract to ensure that market signals about unmet patient need and incentives for R&D are better aligned, and offers recommendations to society, industry and investors to help make this happen. PF4 ran from September 2010 until June 2011 with a diverse group of people and partners. Contributing to the project throughout. The Working Group. PharmaFutures 3 - Eme...
pharmafutures.org
Innovation and productivity in health systems | Pharmafutures
http://pharmafutures.org/pharmafutures-5
Innovation and productivity in health systems. Conclusions of the latest PharmaFutures dialogue: Interview with Sophia Tickell, Director of PharmaFutures. Listen here. Innovation and productivity in health systems. The latest PharmaFutures dialogue extends the analysis of its most recent report, opening up the conversation to include payers, regulators and other societal and government experts as well as assessing new trends in reimbursement, innovation and productivity. PharmaFutures 2 Prescription for ...
pharmafutures.org
Reports and insights | Pharmafutures
http://pharmafutures.org/what-is-pharmafutures/reports-and-insights
Helping align corporate profitability with improved access to innovative and affordable healthcare. Scenario Planning A 20-Year Outlook. Uncovering Value Drivers A 5 to 10 Year Perspective. Identifying Opportunities Exploring Today’s Innovative Models for Value Creation. Shared Value – Rebuilding Pharma’s Contract with Society. Innovation in health systems. Conclusions of the latest PharmaFutures dialogue: Interview with Sophia Tickell, Director of PharmaFutures. Listen here. Explores the long-term press...
pharmafutures.org
What is PharmaFutures? | Pharmafutures
http://pharmafutures.org/what-is-pharmafutures
Helping align corporate profitability with improved access to innovative and affordable healthcare. Scenario Planning A 20-Year Outlook. Uncovering Value Drivers A 5 to 10 Year Perspective. Identifying Opportunities Exploring Today’s Innovative Models for Value Creation. Shared Value – Rebuilding Pharma’s Contract with Society. Innovation in health systems. Each of the PharmaFutures dialogues takes place in a Working Group comprised of asset owners, sell and buy-side analysts of the industry, senior phar...
pharmafutures.org
The Pharmaceutical Sector: A Long-Term Value Outlook | Pharmafutures
http://pharmafutures.org/pharmafutures-1
The Pharmaceutical Sector: A Long-Term Value Outlook. Scenario 1: The producers. Scenario 2: The Patients. Scenario 3: The Politics & Public Health. Background and Project Approach. The Pharmaceutical Sector: A Long-Term Value Outlook. PharmaFutures 1 was a GBN-led scenario planning exercise undertaken by the pharmaceutical industry and its investors in 2004. The project approach. The people and partners. Outlined seven key issues facing the pharmaceutical industry that were relevant for considering the ...
pharmafutures.org
Prescription for Long-Term Value | Pharmafutures
http://pharmafutures.org/pharmafutures-2
Prescription for Long-Term Value. Driver 1: The R&D Landscape. Driver 2: Value for money. Driver 3: Emerging Markets. Background and Project Approach. Prescription for Long-Term Value. PharmaFutures 2 built on the successful formula of PhamaFutures 1, which brought together industry and investors in structured dialogue. However, the approach. To this second phase was to analyse the present operating environment rather than to focus on long-term futures. The overall findings. By the people and partners.
pharmafutures.org
Emerging Opportunities | Pharmafutures
http://pharmafutures.org/pharmafutures-3
Research stream 1: Developing New Business Models. Research stream 2: Partnering with Social Entrepreneurs. Research stream 3: Financing Social Innovation. Background and Project Approach. For PharmaFutures 3: Emerging Opportunities, the people and partners. Involved explored the links between sustainable pharmaceutical business models and improved health outcomes in middle-income markets, including China, India and Brazil. Daniel Summerfield, USS. PharmaFutures 5 explored the healthcare impact of long-t...
SOCIAL ENGAGEMENT